RESTON, Va., July 8 /PRNewswire/ -- BSI announced today that Repligen Corporation, Waltham, MA (Nasdaq: RGEN); the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, the fastest growing segment of the biopharmaceutical industry has achieved BS 25999 certification. Repligen is the first company in North America to have achieved certification for their commitment to ensuring business continuity in the event of disaster or disruption.
BS 25999 is a visionary standard designed to keep your business going during the most challenging and unexpected circumstances. It provides a basis for understanding, developing, implementing and managing business continuity within your organization and gives you confidence when dealing with stakeholders both within and outside your organization. BS 25999 is an auditable standard which means that through certification, you have a framework for continual improvement and the ability to demonstrate to your stakeholders that your BCM program meets globally accepted best practice.
"By earning BS 25999 certification, Repligen is clearly demonstrating their commitment to ensure continued operation in the face of any potential cause of business disruption," said Gary Pearsons, President of BSI Management Systems. "Repligen is the first company in North America to achieve BS 25999 certification. This is just one more example of the leadership role Repligen has earned in their industry. Through the combined strength of Repligen implementing a disciplined management system and BSI providing independent verification and certification; Repligen's stakeholders and customers can be assured of the resiliency of their operations."
"Repligen is a
|SOURCE BSI Management Systems|
Copyright©2008 PR Newswire.
All rights reserved